| Sphingosine-1-phosphate receptor modulator | |
|---|---|
| Drug class | |
 Sphingosine-1-phosphate | |
| Class identifiers | |
| Use | Multiple Sclerosis (MS), psoriasis, Host vs. graft disease, organ transplant |
| ATC code | L04AA |
| Biological target | Sphingosine-1-phosphate receptor |
| Legal status | |
| In Wikidata | |
Sphingosine-1-phosphate receptor modulators are a class of drugs used as immunomodulators, most notably in cases of multiple sclerosis.
These drugs have the ability to modulate the G-protein coupled S1P receptors. Drugs that modulate S1P1 receptors bind to those receptors in lymph nodes and prevent certain lymphoid immune cells from being excreted into the blood and reaching the central nervous system (CNS), leading to lymphopenia.[1][2][3][4]
- ^ Dyckman, Alaric J. (13 July 2017). "Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P 1 ) Agonists and Future Perspectives". Journal of Medicinal Chemistry. 60 (13): 5267–5289. doi:10.1021/acs.jmedchem.6b01575. PMID 28291340.
- ^ Park, Soo-Jin; Im, Dong-Soon (1 January 2017). "Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery". Biomolecules & Therapeutics. 25 (1): 80–90. doi:10.4062/biomolther.2016.160. PMC 5207465. PMID 28035084.
- ^ Adachi, Kunitomo; Chiba, Kenji (6 September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
- ^ Pelletier, Daniel; Hafler, David A. (26 January 2012). "Fingolimod for Multiple Sclerosis". New England Journal of Medicine. 366 (4): 339–347. doi:10.1056/NEJMct1101691. PMID 22276823.